Comparative Pharmacology
Head-to-head clinical analysis: ENDURONYL versus SALURON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENDURONYL versus SALURON.
ENDURONYL vs SALURON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the Na+-Cl− symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption and promoting diuresis.
Saluron (hydroflumethiazide) is a thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule of the nephron, increasing excretion of sodium, chloride, and water. It also reduces peripheral vascular resistance through direct vasodilatory effects.
ENDURONYL (methyclothiazide and deserpidine) is a fixed-dose combination antihypertensive. Typical adult dose: 1 tablet (methyclothiazide 5 mg / deserpidine 0.25 mg) orally once daily. Dose may be increased to 2 tablets once daily if needed.
Initial: 50-100 mg orally once daily; maintenance: 50-200 mg orally once daily or in divided doses.
None Documented
None Documented
Terminal elimination half-life 10-15 hours; clinically, may require 3-5 days to reach steady state in hypertension management.
Terminal elimination half-life is 8-12 hours in adults with normal renal function; prolonged in renal impairment (up to 24-36 hours with creatinine clearance <30 mL/min).
Primarily renal excretion; ~50% unchanged, ~25% as deserpidine metabolites, 20% biliary-fecal.
Primarily renal (≥95%) via glomerular filtration and tubular secretion; approximately 70% as unchanged drug, 25% as metabolites. Biliary/fecal excretion accounts for <5%.
Category C
Category C
Thiazide Diuretic + Rauwolfia Alkaloid
Thiazide Diuretic